Holen Sie sich die Stockscreener-App
29.50
2.08%
0.60
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BAX?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$28.90
Offen:
$29.34
24-Stunden-Volumen:
10.95M
Relative Volume:
2.75
Marktkapitalisierung:
$15.06B
Einnahmen:
$17.28B
Nettoeinkommen (Verlust:
$108.00M
KGV:
5.7843
EPS:
5.1
Netto-Cashflow:
$391.00M
1W Leistung:
-2.70%
1M Leistung:
-9.59%
6M Leistung:
-13.24%
1J Leistung:
-23.58%
1-Tages-Spanne:
$29.17
$29.99
1-Wochen-Bereich:
$28.62
$30.29
52-Wochen-Spanne:
$28.62
$44.01
Baxter International Inc Stock (BAX) Company Profile
Firmenname
Baxter International Inc
Sektor
Telefon
(847) 948-2000
Adresse
ONE BAXTER PKWY, DEERFIELD, IL
Vergleichen Sie BAX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BAX
Baxter International Inc
|
29.50 | 15.06B | 17.28B | 108.00M | 391.00M | 0.20 |
|
ISRG
Intuitive Surgical Inc
|
524.43 | 186.79B | 7.87B | 2.24B | 586.00M | 6.22 |
|
BDX
Becton Dickinson Co
|
227.68 | 65.83B | 20.18B | 1.71B | 3.07B | 5.94 |
|
ALC
Alcon Inc
|
84.76 | 41.92B | 9.76B | 1.16B | 665.00M | 2.34 |
|
RMD
Resmed Inc
|
237.27 | 34.83B | 4.81B | 1.11B | 1.35B | 7.55 |
|
WST
West Pharmaceutical Services Inc
|
331.40 | 24.00B | 2.88B | 499.60M | 321.60M | 6.74 |
Baxter International Inc Stock (BAX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-07-15 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2024-05-30 | Eingeleitet | Goldman | Neutral |
| 2024-05-10 | Herabstufung | TD Cowen | Buy → Hold |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-03-29 | Eingeleitet | UBS | Neutral |
| 2023-01-06 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-01-05 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-01-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-12-19 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-12-15 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2022-12-12 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Hold |
| 2022-06-24 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-04-04 | Herabstufung | Goldman | Neutral → Sell |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2022-02-18 | Bestätigt | KeyBanc Capital Markets | Overweight |
| 2022-02-18 | Bestätigt | Morgan Stanley | Overweight |
| 2022-02-18 | Bestätigt | Raymond James | Outperform |
| 2022-02-18 | Bestätigt | Stifel | Buy |
| 2022-02-18 | Bestätigt | UBS | Neutral |
| 2022-02-18 | Bestätigt | Wells Fargo | Overweight |
| 2022-02-11 | Eingeleitet | Goldman | Neutral |
| 2022-01-07 | Fortgesetzt | Citigroup | Buy |
| 2022-01-07 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-09-13 | Hochstufung | Cowen | Market Perform → Outperform |
| 2021-09-03 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2021-05-25 | Eingeleitet | Barclays | Equal Weight |
| 2021-01-29 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-01-06 | Herabstufung | UBS | Buy → Neutral |
| 2020-12-15 | Herabstufung | Goldman | Buy → Neutral |
| 2020-10-01 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-09-04 | Herabstufung | Argus | Buy → Hold |
| 2020-06-24 | Eingeleitet | Oppenheimer | Outperform |
| 2020-03-19 | Hochstufung | Stifel | Hold → Buy |
| 2020-03-18 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2020-03-05 | Eingeleitet | Citigroup | Neutral |
| 2020-02-13 | Eingeleitet | Goldman | Buy |
| 2020-01-02 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2019-12-17 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-26 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2019-04-08 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-01-02 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-01-02 | Hochstufung | Morgan Stanley | Underweight → Overweight |
| 2018-11-02 | Hochstufung | Argus | Hold → Buy |
| 2018-10-16 | Eingeleitet | Barclays | Underweight |
| 2018-05-17 | Fortgesetzt | Piper Jaffray | Overweight |
| 2018-02-06 | Bestätigt | Citigroup | Neutral |
| 2018-01-03 | Eingeleitet | Evercore ISI | Outperform |
| 2018-01-03 | Hochstufung | Raymond James | Mkt Perform → Outperform |
Alle ansehen
Baxter International Inc Aktie (BAX) Neueste Nachrichten
Investors Purchase Large Volume of Baxter International Put Options (NYSE:BAX) - MarketBeat
Hurricane Helene impact on Baxter to further limit IV fluid supply, HHS says - AOL
Baxter International Inc. stock outperforms competitors despite losses on the day - MarketWatch
Baxter Resumes Production of Peritoneal Dialysis Solutions - DocWire News
Interesting BAX Put And Call Options For August 2025 - Nasdaq
Baxter International Inc. (NYSE:BAX) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat
Baxter International Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Baxter stock hits 52-week low at $29.14 amid market challenges - Investing.com Australia
Parenteral Nutrition Market May Set Epic Growth Story | Baxter, Hospira, Pfizer - openPR
Baxter International Inc. stock outperforms competitors on strong trading day - MarketWatch
Baxter International's SWOT analysis: medical supplies stock faces mixed signals - Investing.com
Baxter International Inc. stock underperforms Monday when compared to competitors - MarketWatch
Baxter International (NYSE:BAX) Hits New 1-Year LowTime to Sell? - MarketBeat
Toronto Dominion Bank Buys 22,787 Shares of Baxter International Inc. (NYSE:BAX) - MarketBeat
Fresenius Can't Stop Baxter's Effort To Save Dialysis Patent - Law360
Baxter Stock May Gain Following Five New Injectable Product Launches - Yahoo Finance
Geode Capital Management LLC Grows Holdings in Baxter International Inc. (NYSE:BAX) - MarketBeat
Advanced Wound Care Management Market Share to Rise At 5.1% CAGR, To Reach USD 17.50 Billion by 2034 | PMR - GlobeNewswire Inc.
Baxter International Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Baxter launches five injectable pharmaceutical products in US - World Pharmaceutical Frontiers
Tympanometer Market Top Companies StudyDemant Group, Baxter International, Oscilla Hearing, Amplifon SpA. - openPR
Baxter Announces Continued Growth of Pharmaceuticals Portfolio With Five Injectable Product Launches in the U.S. - Business Wire
Empire Financial Management Company LLC Buys 19,500 Shares of Baxter International Inc. (NYSE:BAX) - MarketBeat
Baxter Announces Continued Growth of Pharmaceuticals Portfolio with Five Injectable Product Launches in the U.S. - Baxter
Baxter International Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Oversold Conditions For Baxter International (BAX) - Nasdaq
Is the Options Market Predicting a Spike in Baxter International (BAX) Stock? - MSN
Baxter stock touches 52-week low at $31.6 amid market challenges - Investing.com Canada
José Almeida: 100 Most Influential People in Healthcare 2024 - Modern Healthcare
Adalta Capital Management LLC Sells 16,353 Shares of Baxter International Inc. (NYSE:BAX) - MarketBeat
Drug Delivery Market Overview and Leading Players: Baxter - openPR
Hurricane Pauses IV Production At Baxter's North Carolina Facility - MSN
Baxter International Inc. stock underperforms Friday when compared to competitors - MarketWatch
Baxter’s Sascha Hanselmann on championing LGBTQ+ inclusion and building authentic workspaces - attitude.co.uk
Disposable Endoscope Market Report 2024 - GlobeNewswire Inc.
Baxter restarts dialysis solutions production at North Cove plant - MSN
Baxter restarts dialysis solutions production at North Cove plant (NYSE:BAX) - Seeking Alpha
Baxter resumes dialysis solution production at its hurricane-hit facility - Reuters
Finanzdaten der Baxter International Inc-Aktie (BAX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.90%
1.18%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):